BRPI0819212A2 - Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio - Google Patents

Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio

Info

Publication number: BRPI0819212A2
Authority: BR; Brazil
Prior art keywords: treatment; methods; neurogenic inflammation; chronic neurogenic; modified clostridium
Prior art date: 2007-10-23

Application number

BRPI0819212-0A

Other languages

English (en)

Inventor

Kei Roger Aoki

Joseph Francis

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-23

Filing date

2008-10-21

Publication date

2015-06-16

2008-10-21 Application filed by Allergan Inc filed Critical Allergan Inc

2015-06-16 Publication of BRPI0819212A2 publication Critical patent/BRPI0819212A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0819212-0A 2007-10-23 2008-10-21 Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio BRPI0819212A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US98202107P	2007-10-23	2007-10-23
US7622808P	2008-06-27	2008-06-27
US9069208P	2008-09-10	2008-09-10
PCT/US2008/080570 WO2009055350A1 (en)	2007-10-23	2008-10-21	Methods of treating chronic neurogenic inflammation using modified clostridial toxins

Publications (1)

Publication Number	Publication Date
BRPI0819212A2 true BRPI0819212A2 (pt)	2015-06-16

Family

ID=40218954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819212-0A BRPI0819212A2 (pt)	2007-10-23	2008-10-21	Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio

Country Status (11)

Country	Link
US (1)	US20090104234A1 (pt)
EP (1)	EP2214696A1 (pt)
JP (1)	JP2011514307A (pt)
KR (1)	KR20100088683A (pt)
CN (1)	CN101903035A (pt)
AU (1)	AU2008316988A1 (pt)
BR (1)	BRPI0819212A2 (pt)
CA (1)	CA2703364A1 (pt)
IL (1)	IL205280A0 (pt)
MX (1)	MX2010004488A (pt)
WO (1)	WO2009055350A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7811584B2 (en) *	2004-06-30	2010-10-12	Allergan, Inc.	Multivalent clostridial toxins
US8778634B2 (en)	2004-12-01	2014-07-15	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8399400B2 (en)	2004-12-01	2013-03-19	Syntaxin, Ltd.	Fusion proteins
US8603779B2 (en)	2004-12-01	2013-12-10	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8512984B2 (en)	2004-12-01	2013-08-20	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
GB0426394D0 (en) *	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
GB0610867D0 (en)	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain
US8293239B2 (en)	2008-03-04	2012-10-23	Pfizer Limited	Methods of treating chronic pain
US20100303757A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303789A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303798A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US8198229B2 (en) *	2009-05-29	2012-06-12	Allergan, Inc.	Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303756A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303783A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303794A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303791A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
AU2010288194B2 (en)	2009-08-28	2013-08-29	Teva Pharmaceuticals International Gmbh	Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US20120207734A1 (en) *	2011-02-14	2012-08-16	Allergan, Inc.	Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
WO2012112434A1 (en) *	2011-02-14	2012-08-23	Allergan, Inc.	Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20140056870A1 (en)	2012-08-27	2014-02-27	Allergan, Inc.	Fusion proteins
WO2014066916A2 (en)	2012-10-28	2014-05-01	Revance Therapeutics, Inc.	Compositions and methods for safe treatment of rhinitis
US10087432B2 (en)	2012-11-21	2018-10-02	Ipsen Bioinnovation Limited	Methods for the manufacture of proteolytically processed polypeptides
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es)	2014-03-21	2025-03-10	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP6910961B2 (ja) *	2015-05-15	2021-07-28	ヌーテックベンチャーズ	選択細胞への分子送達に適用する遺伝子操作したボツリヌス菌毒素
WO2018039506A1 (en) *	2016-08-24	2018-03-01	President And Fellows Of Harvard College	Engineered botulinum neurotoxin
PE20191148A1 (es)	2016-09-23	2019-09-02	Teva Pharmaceuticals Int Gmbh	Tratamiento de la migrana refractaria
WO2020020878A1 (en) *	2018-07-23	2020-01-30	Universitetssykehuset Nord-Norge Hf	Neurotoxin b for use in the treatment of skin diseases
KR102174197B1 (ko) *	2019-06-12	2020-11-04	주식회사 앤씨비아이티	생산성이 향상된 비독성 프로테아제

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2006A (en) *		1841-03-16		Clamp for crimping leather
US4189426A (en) *	1976-04-12	1980-02-19	Hoffmann-La Roche, Inc.	Recombinant hormonal compositions and method
US4481139A (en) *	1983-04-13	1984-11-06	Board Of Regents, The University Of Texas System	Peptide antagonists of substance P
US4664911A (en) *	1983-06-21	1987-05-12	Board Of Regents, University Of Texas System	Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (ja) *	1984-05-25	1985-12-09	Microbial Chem Res Found	３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
US5668255A (en) *	1984-06-07	1997-09-16	Seragen, Inc.	Hybrid molecules having translocation region and cell-binding region
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4800159A (en) *	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5410019A (en) *	1987-09-24	1995-04-25	The Administrators Of The Tulane-Educational Fund	Therapeutic peptides
US5919665A (en) *	1989-10-31	1999-07-06	Ophidian Pharmaceuticals, Inc.	Vaccine for clostridium botulinum neurotoxin
ATE138102T1 (de) *	1991-02-19	1996-06-15	Takeda Chemical Industries Ltd	Verfahren zur herstellung von cysteinfreien peptiden
CA2112130C (en) *	1991-06-27	1996-08-06	Cynthia A. Edwards	Screening assay for the detection of dna-binding molecules
US5891842A (en) *	1993-04-09	1999-04-06	Trustees Of Tufts College	Methodology for eliciting an analgesic response in a living subject
US5766605A (en) *	1994-04-15	1998-06-16	Mount Sinai School Of Medicine Of The City University Of New York	Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (ja) *	1994-05-02	2001-01-09	アソシエーティドユニバーシティーズ，インコーポレイティド	錫−１１７ｍ−含有放射性治療剤
AU2431995A (en) *	1994-05-09	1995-11-29	William J. Binder	Method for reduction of headache pain
US5538733A (en) *	1994-07-07	1996-07-23	Willmar Poultry Company, Inc.	Method of priming an immune response in a one-day old animal
US5846216A (en) *	1995-04-06	1998-12-08	G & P Technologies, Inc.	Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) *	1995-04-21	1995-06-07	Speywood Lab Ltd	A novel agent able to modify peripheral afferent function
GB9617671D0 (en) *	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
US6063768A (en) *	1997-09-04	2000-05-16	First; Eric R.	Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9818548D0 (en) *	1998-08-25	1998-10-21	Microbiological Res Authority	Treatment of mucas hypersecretion
KR100876060B1 (ko) *	1999-08-25	2008-12-26	알러간, 인코포레이티드	활성화가능한 재조합 신경독
US6641820B1 (en) *	2000-01-19	2003-11-04	Allergan, Inc.	Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) *	2000-01-19	2002-12-31	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) *	2000-01-19	2006-11-21	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US7022329B2 (en) *	2002-02-25	2006-04-04	Allergan, Inc.	Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
EP1830872B1 (en) *	2004-12-01	2010-11-17	Health Protection Agency	Fusion proteins
GB0610867D0 (en)	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain

2008
- 2008-10-21 BR BRPI0819212-0A patent/BRPI0819212A2/pt not_active IP Right Cessation
- 2008-10-21 AU AU2008316988A patent/AU2008316988A1/en not_active Abandoned
- 2008-10-21 WO PCT/US2008/080570 patent/WO2009055350A1/en not_active Ceased
- 2008-10-21 JP JP2010531157A patent/JP2011514307A/ja active Pending
- 2008-10-21 KR KR1020107010958A patent/KR20100088683A/ko not_active Withdrawn
- 2008-10-21 CA CA2703364A patent/CA2703364A1/en not_active Abandoned
- 2008-10-21 CN CN2008801212895A patent/CN101903035A/zh active Pending
- 2008-10-21 EP EP08842727A patent/EP2214696A1/en not_active Withdrawn
- 2008-10-21 MX MX2010004488A patent/MX2010004488A/es unknown
- 2008-10-21 US US12/255,033 patent/US20090104234A1/en not_active Abandoned
2010
- 2010-04-22 IL IL205280A patent/IL205280A0/en unknown

Also Published As

Publication number	Publication date
MX2010004488A (es)	2010-06-17
WO2009055350A1 (en)	2009-04-30
KR20100088683A (ko)	2010-08-10
US20090104234A1 (en)	2009-04-23
CN101903035A (zh)	2010-12-01
AU2008316988A1 (en)	2009-04-30
IL205280A0 (en)	2010-12-30
JP2011514307A (ja)	2011-05-06
EP2214696A1 (en)	2010-08-11
CA2703364A1 (en)	2009-04-30

Publication	Publication Date	Title
BRPI0819212A2 (pt)	2015-06-16	Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio
IL281675A (en)	2021-05-31	Injectable botulinum toxin formulations
BRPI0817775A2 (pt)	2015-03-24	Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
BRPI0910259A2 (pt)	2015-12-01	métodos de tratamento de inflamação
EP2167528A4 (en)	2011-01-19	MODIFIED TOXINS
BR112012001325A2 (pt)	2017-05-02	tratamento de distúrbios do fígado com inibidaores de pi3k
EP2419128A4 (en)	2012-02-22	REMOVED BOTULINUM NEUROTOXIN
BRPI0917130A2 (pt)	2015-12-01	biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados
PL2190883T3 (pl)	2015-04-30	Sposób obróbki biomasy
EP2424873A4 (en)	2013-05-08	NOVEL GALECTIN GALACTOSIDHEMMER
EP2134446A4 (en)	2011-04-06	BIOGAS PROCESSING
BRPI0910854A2 (pt)	2015-10-06	métodos de tratamento
DK2069798T3 (da)	2014-06-16	Elisa til vegf
DK2293816T3 (da)	2013-02-04	Fremgangsmåder til behandling af reumatoid arthritis
HUE036477T2 (hu)	2018-07-30	Monoklonális anti-GT468 antitestek rák kezeléséhez
DK2337837T3 (da)	2013-06-24	Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
DK3276004T3 (da)	2020-04-06	Fremgangsmåder til behandling af kronisk nyresygdom
EP2268297A4 (en)	2011-11-16	MODIFIED TOXINS
EP2385831A4 (en)	2014-03-26	SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
BR112012004246A2 (pt)	2016-04-05	métodos para tratar inflamação neurogênica crônica usando uma toxina clostridial modificada
BRPI0923635A2 (pt)	2018-10-16	pesquisa audiovisual e interface de navegação
EP2291957A4 (en)	2013-10-09	MEDIA PROCESSING POWER
DE112009003766T8 (de)	2012-10-25	Sputter-Vorrichtung und Sputter-Verfahren
BRPI1010516A2 (pt)	2015-08-25	Métodos de tratamento de edema relacionados à isquemia-reperfusão
EP2146744A4 (en)	2012-07-25	THERAPEUTIC BETA-GLUCAN COMPOSITIONS

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.